Highest-materiality recent filing
Martin Bonick's employment terminated June 2, 2026; separation agreement signed June 26, 2026.
Ardent Health appoints Dave Caspers as CEO, reaffirms FY 2026 EBITDA guidance
Dave Caspers appointed President and CEO, effective June 2, 2026, succeeding Marty Bonick.
Ardent Health Q1 2026: Revenue $1.60B (+7%), Adjusted EBITDA $124M (+26%), Reaffirms FY Guidance
Total revenue $1.602B (+7.0% YoY); net income $40M ($0.28 diluted EPS) vs $41M ($0.29) a year ago.
Ardent Health Q4 adj EBITDA down 26.6% to $134M; 2026 guidance issued
Q4 total revenue $1.605B (flat YoY); net income $45M vs $114M prior year.
Ardent Health authorizes $50M share repurchase program; $609M cash on hand
Board authorized up to $50M in common stock repurchases; no expiration date.
Ardent Health Q3 net loss $23M; cuts 2025 adj. EBITDA guidance to $530-555M
Revenue $1.58B (+8.8% YoY); net loss attributable of $23M vs net income $26M in Q3 2024.
Ardent Health amends $777.5M term loan facility; rate cut 50 bps, maturity extended to 2032
Interest rate reduced by 50 bps to Term SOFR + 2.25%; expected annual interest savings of ~$3.9M.
Ardent Health Q2 revenue up 12% to $1.65B; Adj EBITDA +39% to $170M; reaffirms FY25 guidance
Net income $73M ($0.52 diluted EPS) vs $43M ($0.34) prior year; adjusted EBITDA $170M.
Ardent Health Q1 net income $41M, revenue $1.50B up 4% YoY; reaffirms FY guidance
Net income attributable to Ardent Health $41M ($0.29 diluted EPS), up from $27M a year ago.
Ardent Health Q4 revenue $1.61B (+19% YoY); Adj EBITDA $183M (+213%); issues 2025 guidance
Q4 net income $114M ($0.81 diluted EPS) vs net loss $4M in Q4 2023.
Ardent Health provides preliminary 2025 guidance; CMS approves NM directed payment program
CMS approved New Mexico directed payment program for July-December 2024; material Q4 financial benefit expected, amount not yet disclosed.
Ardent Health Q3 revenue $1.45B (+5.2%); adj. EBITDA $98M (+15.3%)
Net income of $26M ($0.19 per share); cash from ops of $90M.
Ardent Health Q2 revenue $1.47B, adj. EBITDA $122M (+20%); issues FY24 guidance
Q2 revenue $1.47B (+7.5% YoY); net income attributable $43M ($0.34/share).
Mr. Caspers succeeds Martin J. Bonick, who separated from the Company and stepped down from the Board effective as of the Effective Date.
On June 2, 2026 (the “Effective Date”), the Board of Directors (the “Board”) of Ardent Health, Inc. (the “Company”) appointed Dave Caspers, who previously served as the Company’s Chief Operating Officer, as the Company’s President and Chief Executive Officer and as a member of the Board.
On June 16, 2025, Ardent Health, Inc. (the “Company”) and David Schultz determined that Mr. Schultz would no longer serve as President, Hospital Operations and would depart the Company effective immediately.
it has increased the size of the Company’s Board of Directors (the "Board") to 11 members and has appointed Robert A. DeMichiei to fill the newly created seat on the Board, effective April 2, 2025.
On March 31, 2025, Ardent Health Partners, Inc. (the “Company”) announced that David Caspers, 54, has been appointed as the Company’s Chief Operating Officer, effective March 31, 2025.
Max materiality 0.85 · Median 0.65 · Most common event earnings